CVs Health has earned #50 in the ranking for DiversityInc's 2017 Top 50 Companies for Diversity. This is the first time that CVS has been on the list, though it was #25 on the Noteworthy listing in the past. Read More »

Teva Pharmaceutical Industries Ltd.'s results from a Phase II/III study ARM-TD (Aim to Reduce Movement in Tardive Dyskinesia) have been published in Neurology, the American Academy of Neurology's medical journal. Read More »

A major pharmacy benefit manager has announced a program to provide discounted drugs to uninsured Americans. Read More »

Pharmacy benefit managers should be praised for helping to keep down the cost of prescription drugs, rather than attacked by Congress and others, according to one health policy adviser. Read More »

Imprimis Pharmaceuticals Inc., and SightLife Surgical have signed a sales and marketing agreement in which SightLife will be offering Imprimis' autologous eye drops, Serum Tears, which have been specially formulated for patients suffering from chronic dry eye who require more than traditional treatment. Read More »

Celgene Corporation recently announced that the primary endpoint has been met for its Phase III Sunbeam trial, which evaluated the efficacy and safety of ozanimod, an investigational oral, selective S1P 1 and 5 receptor modulator, in patients with relapsing multiple sclerosis (RMS). Read More »

Sunovion Pharmaceuticals Inc., five leading mental health advocacy organizations and singer, songwriter and mental health advocate Demi Lovato recently released "Beyond Silence," a documentary about their experience with speaking out for mental health. Read More »

Kaiser Permanente has published research in JAMA Pediatrics that showcases the development of a neonatal sepsis risk calculator that has safely reduced antibiotic use by nearly 50 percent in newborns. Read More »

The U.S. Food and Drug Administration has accepted Pfizer's Biologics License Application for inotuzumab ozogamicin. Read More »

Mylan's Biologics License Application for MYL-1401H, a proposed biosimilar to Neulasta (pegfilgrastim), has been accepted by the U.S. Food and Drug Administration. Read More »

AbbVie, a global biopharmaceutical company, recently announced its Viekirax + Exviera eight-week treatment program has been granted a positive opinion by the European Committee for Medicinal Products for Human Use of the European Medicines Agency. Read More »

Pfizer Inc. recently released top-line results for ORAL Strategy, a Phase 3B/4 study of XELJANZ (tofacitinib citrate) 5mg twice daily in the treatment of moderate to severe rheumatoid arthritis. Read More »

The European Commission has adopted a decision to change the Repatha (evolocumab) marketing authorization, approving a new single-dose delivery option. Read More »

Purdue Pharma L.P.'s Maria Barton has been promoted from deputy general counsel to general counsel. Read More »

Genentech, a member of the Roche Group, recently announced its Phase II IMmotion150 study delivered promising results. Read More »

The biggest pharmaceutical event series in the world, the CPhl, will take place May 16-18 in Philadelphia and feature over 55 speakers. Read More »

PharmaCyte Biotech, Inc., announced that they would be winning the 2017 Buzz of BIO "Pipelines of Promise" award prior to the 2017 BIO International Convention. Read More »

BioPharmX Corp., a leading pharmaceutical company developing and promoting health products for the dermatology and women’s market, revealed it has completed the “last subject visit in its Phase 2b trial,” as of March. Read More »

DelMar Pharmaceuticals Inc., a company fighting for cancer patients and therapies, decreased its public stock aggregate share from 2.77 million to 2.08 million this month. Read More »

Amgen and Novartis are working together to fight against migraines with erenumab, an expanded commercial collaboration building on a global neuroscience collaboration in Alzheimer's disease and migraine established in 2015. Read More »